Filing Details

Accession Number:
0001181431-11-058855
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-12-05 19:48:53
Reporting Period:
2011-12-01
Filing Date:
2011-12-05
Accepted Time:
2011-12-05 19:48:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178711 Transcept Pharmaceuticals Inc TSPT Pharmaceutical Preparations (2834) 330960223
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1408920 T Joseph Kennedy C/O Transcept Pharmaceuticals, Inc.
1003 W. Cutting Blvd
Point Richmond CA 94804
Vp And General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-12-01 4,150 $2.68 4,150 No 4 M Direct
Common Stock Disposition 2011-12-01 4,150 $8.23 0 No 4 S Direct
Common Stock Acquisiton 2011-12-01 56,666 $3.10 56,666 No 4 M Direct
Common Stock Disposition 2011-12-01 56,666 $8.23 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee stock option (right to buy) Disposition 2011-12-01 4,150 $0.00 4,150 $2.68
Common Stock Employee stock option (right to buy) Disposition 2011-12-01 56,666 $0.00 56,666 $3.10
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
38,750 2021-08-24 No 4 M Direct
28,334 2019-03-12 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 12, 2011.
  2. The sales price reported in column 4 of Table 1 represents the weighted average sales price of the shares sold ranging from $8.52 to $8.00 per share. Upon request of the commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. Fifty percent of the option vests upon approval by the U.S. Food and Drug Administration of Intermezzo (R) and the remaining fifty percent vests on the first anniversary of any such approval; provided in each case, such approval occurs no later than August 24, 2013. Approval by the U.S. Food and Drug Administration of Intermezzo (R) occurred on November 23, 2011.
  4. One fourth of the shares subject to the option vested on March 6, 2010 and one forty-eighth of the shares vest monthly thereafter.